Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

NCT02250807 is registered in ClinicalTrials.gov with Janssen R&D Ireland as lead sponsor.

NCT NCT02250807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02250807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection
Lead sponsor
Janssen R&D Ireland
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2015
Completion date
December 31, 2015
Enrollment
40 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c, genotype 4 chronic hepatitis c